Search Daily Dose & Film Annex

BIO SmartBrief

Daily Dose Newsletter


4 Reasons To Buy Ventrus Biosciences - Update @ Seeking Alpha

Ventrus Biosciences (NASDAQ: VTUS) is a development stage specialty pharmaceutical company focused on the development of late-stage prescription drugs.

Today Markus Aarnio posted an update Ventrus @ Seeking Alpha:

"I wrote the article titled "4 Reasons To Buy Ventrus Biosciences" on May 21st. On June 25 Ventrus Biosciences (VTUS) reported that its Phase 3, randomized, double-blind, placebo-controlled clinical trial of iferanserin (VEN 309) in patients with hemorrhoidal disease did not meet its endpoints.

While the company intends to analyze the totality of its Phase 3 data further, it believes that current resources would be better allocated toward the planned completion of its VEN 307 (diltiazem cream) development program in anal fissures and the beginning of further development of VEN 308 (topical phenylephrine) in fecal incontinence. Consequently, Ventrus has no immediate plans to continue development of VEN 309, resulting in a reduction in expenses.

Conclusion - I believe the stock could trade at $8-$10 range in the best case scenario after VEN-307 approval sometime in 2014. I do not expect any major near term catalysts from the company before late 2013."

See the full story at Seeking Alpha.

PrintView Printer Friendly Version

EmailEmail Article to Friend

Reader Comments (1)

Thanks for your publishing on this website. From my own encounter, many times conditioning up a picture might perhaps offer the photographer with a bit of an arty width. Regularly however, the smooth reasoning is certainly not just what exactly you had into concern and might mess up a normally fantastic picture, especially if you considering enhancing them.

July 19, 2012 | Unregistered CommenterSTOCK MARKET

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>
« What the Shire announcement means for Intellipharmaceutics International (NASDAQ: IPCI; TSX: I) | Main | Interview with Jeffrey Davis, CEO of Access Pharmaceuticals June 2012 – MuGard MASCC Data - $ACCP »